Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Cardiff Oncology's Sloan Ratio for the quarter that ended in Mar. 2026 was -53.95%.
As of Mar. 2026, Cardiff Oncology has a Sloan Ratio of -53.95%, indicating there is a warning stage of accrual build up.
Cardiff Oncology (NAS:CRDF) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, Cardiff Oncology has a Sloan Ratio of -53.95%, indicating there is a warning stage of accrual build up.
Cardiff Oncology Sloan Ratio % Related Terms
Cardiff Oncology Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Cardiff Oncology's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRDF vs MNOV, PMVP, CING: Sloan Ratio % Comparison
For the Biotechnology subindustry, Cardiff Oncology's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology Sloan Ratio % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Cardiff Oncology's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Cardiff Oncology's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was -13.943 (Jun. 2025 ) + -11.258 (Sep. 2025 ) + -7.216 (Dec. 2025 ) + -12.345 (Mar. 2026 ) = $-44.76 Mil.
Cardiff Oncology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was -8.328 (Jun. 2025 ) + -10.834 (Sep. 2025 ) + -5.967 (Dec. 2025 ) + -12.288 (Mar. 2026 ) = $-37.42 Mil.
Cardiff Oncology's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was -4.983 (Jun. 2025 ) + 10.16 (Sep. 2025 ) + 10.749 (Dec. 2025 ) + 3.257 (Mar. 2026 ) = $19.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology (CRDF) has a Sloan Ratio % of -53.95% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Cardiff Oncology and its competitors.
Is Cardiff Oncology's Sloan Ratio % too high?
Cardiff Oncology's current Sloan Ratio % is -53.95%. Overall, Cardiff Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Sloan Ratio % compare to MNOV and PMVP?
Cardiff Oncology's Sloan Ratio % of -53.95% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Biotechnology company?
A good Sloan Ratio % depends on the Biotechnology industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Cardiff Oncology and its competitors. Cardiff Oncology's current Sloan Ratio % is -53.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (CRDF) has a current Sloan Ratio % of -53.95%. The current Sloan Ratio % is -53.95%. Cardiff Oncology's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Sloan Ratio % is -53.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
31GF Score
Get the complete analysis for CRDF
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 
